Percorrer por data de Publicação, começado por "2024-08-15"
A mostrar 1 - 2 de 2
Resultados por página
Opções de ordenação
- Mercury exposure assessment from the first harmonised Total Diet Study in PortugalPublication . Vasco, Elsa; Dias, Maria da Graça; Oliveira, LuísaThe aim of this study was to estimate the Portuguese population’s baseline exposure to methyl and inorganic mercury by a harmonised total diet study (TDS) methodology and the risk of exceeding the Tolerable Weekly Intake (TWI). TDS food samples representative of the whole diet of the population were prepared as consumed, and analysed for total mercury. European Food Safety Authority’s (EFSA) conservative approach was used to estimate methylmercury and inorganic mercury and exposure was estimated using Monte Carlo Risk Assessment (MCRA) software. Mean, median and P95 exposure of the overall population (18 to 74 years old) to methylmercury and to inorganic mercury were 1.25, 0.01 and 5.45 µg/kg bw/week, and 0.37, 0.15 and 1.27 µg/kg bw/week, respectively. The percentage of individuals exceeding TWI was 27.6 for methylmercury and 3.5 for inorganic mercury. Regarding childbearing age women (18 to 45 years old), methylmercury mean exposure was 1.13 µg/kg bw/week with 25% of women exceeding the TWI. Cod and hake were the main contributors to mercury intake.
- Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024Publication . Antunes, Liliana; Mazagatos, Clara; Martínez‐Baz, Iván; Naesens, Reinout; Borg, Maria‐Louise; Petrović, Goranka; Fatukasi, Terra; Jancoriene, Ligita; Machado, Ausenda; Oroszi, Beatrix; Husa, Petr; Lazar, Mihaela; Dürrwald, Ralf; Howard, Jennifer; Melo, Aryse; Pérez‐Gimeno, Gloria; Castilla, Jesús; Bernaert, Eva; Džiugytė, Aušra; Makarić, Zvjezdana Lovrić; Fitzgerald, Margaret; Mickienė, Auksė; Gómez, Verónica; Túri, Gergő; Součková, Lenka; Marin, Alexandru; Tolksdorf, Kristin; Nicolay, Nathalie; Rose, Angela M.C.; European Hospital Vaccine Effectiveness GroupWe conducted a multicentre test-negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14–29days and 40% at 60–105days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5months post vaccination, with VE>70% in older adults (≥65 years) up to 1month post vaccination.